Efficacy of a glucose meter connected to a mobile app on glycemic control and adherence to self-care tasks in patients with T1DM and LADA: a parallel-group, open-label, clinical treatment trial

The main aim of the study was to evaluate the patients' glycemic control and adherence to self-care tasks. Patients with type 1 diabetes mellitus (T1DM) or latent autoimmune diabetes of the adult (LADA) using a multiple daily injection (MDI) regimen with carbohydrate counting (n = 25, Subgroup...

Full description

Saved in:

Bibliographic Details
Published in:	Archives of Endocrinology and Metabolism Vol. 65; no. 2; pp. 185 - 197
Main Authors:	de Oliveira, Felipe Martins, Calliari, Luís Eduardo Procópio, Feder, Cecília Kauffman Rutenberg, de Almeida, Maria Fernanda Ozorio, Pereira, Mariana Vilela, de Almeida Fagundes Alves, Maria Thereza Teixeira, Garcia, Sônia Aparecida Dias, Reis, Ligia Dinara Donizeti, Salles, João Eduardo Nunes
Format:	Journal Article
Language:	English
Published:	Brazil Sociedade Brasileira de Endocrinologia e Metabologia 01-03-2021 Brazilian Society of Endocrinology and Metabolism
Subjects:	Adult blood glucose Blood Glucose - analysis Diabetes mellitus, type 1 Diabetes Mellitus, Type 1 - drug therapy Glycated Hemoglobin - analysis glycated hemoglobin A Glycemic Control Humans Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Insulin Infusion Systems Mobile Applications Original Self Care self-management treatment adherence and compliance blood glucose glycated hemoglobin A treatment adherence and compliance self-management Diabetes mellitus, type 1
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The main aim of the study was to evaluate the patients' glycemic control and adherence to self-care tasks. Patients with type 1 diabetes mellitus (T1DM) or latent autoimmune diabetes of the adult (LADA) using a multiple daily injection (MDI) regimen with carbohydrate counting (n = 25, Subgroup B) or fixed insulin dose (n = 25, Subgroup C) were allocated to use the application (app) for 12 weeks. Both subgroups were compared with each other and against a control group (n = 25, Group A) comprising patients with T1DM or LADA treated with continuous subcutaneous insulin infusion (CSII) in a parallel-group, open-label, clinical treatment trial. All patients had glycated hemoglobin (A1C) levels measured and were asked to fill out the Diabetes Self-Management Profile (DSMP) questionnaire at study start and end. The patients were instructed to measure capillary glucose six times daily in study weeks 4, 8, and 12. Mean A1C levels decreased 0.725% in Subgroup C in intragroup analysis (p = 0.0063), and had a mean variation of 0.834% compared with Group A (p = 0.003). Mean DSMP scores increased 5.77 points in Subgroup B in intragroup analysis (p = 0.0004) and increased by a mean of 6.815 points in relation to Group A (p = 0.002). OneTouch Reveal improved both A1C levels and DSMP scores in patients with T1DM or LADA compared with standard treatment (CSII).
Bibliography:	Disclosure: no potential conflict of interest relevant to this article was reported.
ISSN:	2359-3997 2359-4292
DOI:	10.20945/2359-3997000000334